Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors

References

• Stewart S, MacIntyre K, Hole D, Capewell S, Mc Murray J. More “malignant” than cancer? Five-year survival follow-ing a first admission for heart failure. Eur J Heart Failure 2001; 3: 315–22.
   Google Scholar
• McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs R, Maggioni A, Pina I, Soler-Soler J, Swedberg K. Practical recommendations for the use of ACE inhibitors, beta-blockers and spirono-lactone in heart failure: putting guidelines into practice. Eur J Heart Failure 2001; 3: 495–502.
   Google Scholar
• CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429–35.
   Google Scholar
• Erdmann E. Indications for ACE inhibitors in chronic heart failure [in German]. Z Kardiol 1994; 83, Suppl 4: 75–9.
   Google Scholar
• Hopf R. Progposeverbesserung mit ACE-Hemmern bei kar-dialer Dysfunktion: Neue Erkenntnisse durch die AIRE-Studie. Medikon Verlag, Miinchen, 1993.
   Google Scholar
• Huber K, Pachinger O, Pichler M, Klein W. Pathophysio-logical mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases [in German]. Z Kardiol 1997; 86: 239–50.
   Google Scholar
• Linz W, Wiemer G, Gohlke P, Unger T, Scholkens B. Car-dioprotective effects by ramipril after ischemia and reperfu-sion in animal experiment studies [in German]. Z Kardiol 1994; 83 Suppl 4: 53–6.
   Google Scholar
• Pfeffer MA, Braunwald E, Moye’L, Basta L, Brown E, Cuddy T, Davus B, Geltman E, Goldman S, Raker G. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–77.
   Google Scholar
• SOLVD Investigators. Effekt of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–9.
   Google Scholar
• Brunner-La Rocca HP, Weilenmann D, Kiowski W, Maly FE, Candinas R, Follath F. Within-patient comparison of effects of different dosages of enalapril on functional capac-ity and neurohormone levels in patients with chronic heart failure. Am Heart J1999; 138: 654-62.
   Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waag-stein F, Kjekshus J, Wilkstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselmann DH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart fail-ure. The metoprolol CRAL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. J Am Med Assoc 2000; 283: 1295–302.
   Google Scholar
• The CAPRICORN Investigators. Effects of cardevilol on outcome after myocardial infarct in patients with left ven-tricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385–90.
   Google Scholar
• Schachter M. ACE inhibitors, angiotensin receptor antago-nists and bradykinin. J Renin Angiotensin Aldosterone Syst 2000; 1: 27–9.
   Google Scholar
• B8nner G. Bedeutung der Kinine fiir die Wirkung der ACE-Hemmer. In: Dominiak P, Milner G, eds. ACE-Hemmer in Klinik und Praxis, Springer-Verlag Berlin-Heidelberg 1995: pp. 37-54.
   Google Scholar
• Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Her-ras M, Sanz G. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J2000; 21: 53-7.
   Google Scholar
• Hanon S, Vijayaraman P, Sonnenblick EH, LeJemtel TH. Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chmnic heart failure. J Renin Angiotensin Aldosterone Syst 2000; 1: 147–50.
   Google Scholar
• Nussberger J, Juillerat L, Perret F, Waeber B, Benet M, Brun-ner J, Menard J. Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans. Am Heart J 1989; 117(3): 712–22.
   Google Scholar
• Dzau VJ, Re R. Tissue angiotensin system in cardiovascu-lar medicine: a paradigm shift? Circulation 1994; 89: 493–8.
   Google Scholar
• Dendorfer A, Simon M, Dominiak P. Cardioactive hormones: bradykinin [in German]. Z Kardiol 1996; 85 Suppl 6: 211–8.
   Google Scholar
• Dominiak P, Dendorfer A. Pharmakologie und klinische Pharmakologie der AT1-Rezeptorantagonisten. In: Dominiak P, Unger Th, eds. AT1-Rezeptorantagonisten Angiotensin II. Steinkopff Verlag Darmstadt 1997; pp. 41-73.
   Google Scholar
• Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153: 937–42.
   Google Scholar
• Schieffer B, Drexler H. Pathophysiologie der chronischen Herzinsuffizienz. In: Dominiak P, Unger Th, eds. AT1-Rezeptorantagonisten Angiotensin II. Steinkopff Verlag Darmstadt 1997; pp. 129-37.
   Google Scholar
• Calif RM, Cohn JN. Cardiac protection: evolving role of angiotensin receptors blockers. Am Heart J2000; 139 (lPt 2): 15-22.
   Google Scholar
• Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11 Sup-plement 3: S 13-8.
   Google Scholar
• Griendling KK, Lassegue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Phar-macol Toxicol 1996; 36: 281–306.
   Google Scholar
• Regitz-Zagrosek V, NeuB M, Warnecke C, Holzmeister J, Hildebrand AG, Fleck E. Angiotensin receptors-organ and subtype specific regulation in cardiovascular diseases by modulation of the renin-angiotensin system. Studies of the rat model and in human myocardium. Z Kardiol 1995; 84 Suppl 4: 61–9.
   Google Scholar
• Timmermans P, Wong P, Chiu A, Herblin W, Benfield P, Carini D, Lee R, Wrexler R, Saye JA, Smith R. Angiotensin II receptors and angiotensin II receptor antagonists. Phar-macol Rev 1993; 45(2): 205–51.
   Google Scholar
• Parker AB, Azevedo ER, Baird MG, Smith S, Arnold J, Humen D, Moe G, Parker JO, Butt R, Parker JD. ARCTIC: assessment of haemodynamic response in patients with con-gestive heart failure to telmisartan: a multicentre dose-rang-ing study in Canada. Am Heart J1999, 138: 843-8.
   Google Scholar
• Willenbrock R Philipp S, Mitrovic V, Dietz R. Neurohu-moral blockade in CHF management. J Renin Angiotensin Aldosterone Syst 2000; 1(suppl 1): 24-30.
   Google Scholar
• Ohlstein E, Brooks D, Feuerstein G, Ruffalo R. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: Possible relationship to differences in pre-junc-tional angiotensin II receptor blockade. Pharmacology 1997; 55: 244–52.
   Google Scholar
• Packer M. The neurohormonal hypothesis: a theory to explain the mechanisms of disease progression in heart fail-ure. J Am Coll Cardiol 1992; 20: 248–54.
   Google Scholar
• Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart fail-ure. N Engl J Med 1996; 334: 1349–55.
   Google Scholar
• Pizzulli L, Luderitz B. Secondary prevention of coronary artery disease [in German]. Dtsch Arztebl 1998; 95 (issue 27): A-1732-1738.
   Google Scholar
• Sigmund M, Hanrath P. Beta receptor blockers in chronic heart failure [in German]. Z Kardiol 1995; 84: 820–6.
   Google Scholar
• de Gasparo M, Hess P, Nuesslein-Hildesheim B, Bruneval P, Clozel JP. Combination of non-hypotensive doses of val-sartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. J Renin Angiotensin Aldosterone Syst 2000; 1: 151–8.
   Google Scholar
• Shen YT, Wiedmann RT, Greenland BD, Lynch JJ, Gross-mann W Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in con-scious pigs with congestive heart failure. Cardiovasc Res 1998; 39(2): 413–22.
   Google Scholar
• Weidenbach R, Schulz R, Gres P, Behrends M, Post H, Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT1-receptor antagonism. Brit J Pharmacol 2000; 131: 138–44.
   Google Scholar
• Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short-and long-term hemodynamic and hor-monal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-Heft) Study Group. Circulation 1999; 99: 2658–64.
   Google Scholar
• Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari M, Thomas S, LeJemtel T. Addition of angiotensin II receptor blockade to maximal angiotensin converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990–2.
   Google Scholar
• Gremmler B, Kunert M, Schleiting H, Ulbricht U. Improve-ment of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1 antago-nist eprosartan. Eur J Heart Failure 2000; 2: 183–7.
   Google Scholar
• Weinberg M, Weinberg A, Zappe D. Effectively targeting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using Angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst 2000; 1: 217–33.
   Google Scholar
• Cohn JN, Tognoni G, Glazer RD, Sporman D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortal-ity in chronic congestive heart failure. J Card Fail 1999; 5: 155–60.
   Google Scholar
• Pitt B, Poole-Wilson P, Segal R, Martinez F, Dickstein K, Camm A, Kostam M, Riegger G, Klinger G, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival study ELITE II. Lancet 2000; 355: 1582–7.
   Google Scholar
• Swedberg K, Pfeffer M, Granger C, Held P, McMurry J, Ohlin G, Olofsson B, Ostergren J, Yusuf S. Candesartan in heart failure-assessment of reduction in mortality and mor-bidity (CHARM): rationale and design. J Card Fail 1999; 5: 276–82.
   Google Scholar
• Pfeffer MA. Enhancing cardiac protection after myocardial infarction: Rationale for newer clinical trials of angiotensin receptor blockers. Am Heart J 2000; 1139(lpt2): 23-8.
   Google Scholar
• Mc Kelvie RS, Yusuf S, Pericak D, Avezum A, Burns R, Probstfield J, Tsuyuki R, White M, Rouleau J, Latini R, Maggioni A, Joung J, Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomised evaluation of strategies for the left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study investigators. Circulation 1999; 100: 1056–64.
   Google Scholar
• Ball S. Should all patients with heart failure now receive an ACE inhibitor? Eur J Heart Fail 2001; 3: 645–6.
   Google Scholar
• Cohn J, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–75.
   Google Scholar
• Farquharson CAJ, Struthers AD. Angiotensin II receptor blockers in chronic heart failure - Not as ELITE as expected! J Renin Angiotensin Aldosterone Syst 2000; 1: 21–2.
   Google Scholar
• McMurray J, Berry C. Ongoing clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction. J Renin Angiotensin Aldosterone Syst 2000; 1: 131–6.
   Google Scholar
• Knapp E. Impedance cardiography [in German]. Wien Klin Wochenschr Suppl 1976; 58: 1–15.
   Google Scholar
• Horstmann E. Impedance cardiography during exercise in the evaluation of left-ventricular function [in German]. Z Kardiol 1984; 73: 374–9.
   Google Scholar
• Löllgen H. Kardiopulmonale Funktionsdiagnostik. Edition CIBA, Wehr/Baden, 1983.
   Google Scholar